Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow.
about
Donor hematopoiesis in mice following total lymphoid irradiation requires host T-regulatory cells for durable engraftment.Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacementTransplantation tolerance: from theory to clinic.Pretransplant mobilization with granulocyte colony-stimulating factor improves B-cell reconstitution by lentiviral vector gene therapy in SCID-X1 mice.An MHC-defined primate model reveals significant rejection of bone marrow after mixed chimerism induction despite full MHC matchingPlatelets, acting in part via P-selectin, mediate cytomegalovirus-induced microvascular dysfunction.Prevention of Transplant Rejection: Can Tolerance be Achieved with Immunosuppressive Treatment?NAD(P)H oxidase and eNOS play differential roles in cytomegalovirus infection-induced microvascular dysfunctionRole of blood- and tissue-associated inducible nitric-oxide synthase in colonic inflammation.Mobilization as a preparative regimen for hematopoietic stem cell transplantationA Depleting Anti-CD45 Monoclonal Antibody as Isolated Conditioning for Bone Marrow Transplantation in the Rat.Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.Purified hematopoietic stem cell engraftment of rare niches corrects severe lymphoid deficiencies without host conditioning.Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.A novel competitive repopulation strategy to quantitate engraftment of ex vivo manipulated murine marrow cells in submyeloablated hosts.Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunityPerivascular, but not parenchymal, cerebral engraftment of donor cells after non-myeloablative bone marrow transplantationMixed chimerism and tolerance without whole body irradiation in a large animal model.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.IL-2 pathway blocking in combination with anti-CD154 synergistically establishes mixed macrochimerism with limited dose of bone marrow cells and prolongs skin graft survival in miceHematopoietic cell transplantation for tolerance induction: animal models to clinical trialsTranslational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.Defective pulmonary innate immune responses post-stem cell transplantation; review and results from one model system.Immune tolerance in recipients of combined haploidentical bone marrow and kidney transplantation.Extrinsic regulation of hematopoietic stem cells in development, homeostasis and diseases.Limited efficacy and unacceptable toxicity of cyclophosphamide for the induction of mixed chimerism and renal allograft tolerance in cynomolgus monkeys.Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine.Rapid lymphocyte reconstitution of unconditioned immunodeficient mice with non-self-renewing multipotent hematopoietic progenitors.Effects of sublethal irradiation on patterns of engraftment after murine bone marrow transplantationHSC niche: ample room for every guest stem cell.
P2860
Q33556957-B06C73C2-CFDB-4673-AC5B-C248326BB3D5Q34021167-90ED4084-6F58-4EBD-A5F7-237A6E0FCD1CQ34082059-D95F9240-9880-4EBF-880E-4C1EB8268349Q34268121-E0AC8A8B-928D-495C-B08B-B6F64FC9699FQ34307416-12E3837C-07DA-42C2-B6EF-890511B8A3BEQ34726933-EB4D79DE-9D3C-4E36-8525-05002405FEAEQ34962270-2E467D98-D745-403D-9A4D-98ABA4E08468Q35738597-D665D808-1DF8-4806-B340-E3A5D119AD37Q35750187-C62883C7-F9C6-497F-8EE7-09750036D553Q35849647-509FE6B9-01F0-49D7-A465-4401E3404E3EQ36006801-06F2F183-1FF7-46A1-9F9C-2F5950B28253Q36166303-15676DD0-9379-488A-A6D0-9D0390ABD60AQ36227853-1D4E773F-46C2-427D-85C1-ADCC1F8FEB30Q36401145-E9579825-C9A3-42D3-B251-2616E6D6D291Q36640242-B001CA34-F50F-49D1-981C-FC0525657A25Q36915859-C2D66480-2126-4CA9-AB32-12CA8DA5698EQ36997172-D965855C-63E0-430E-8106-B96F1FBDB6AAQ37202108-44A565CD-12FF-4C3A-8F97-9E410B6DFDDCQ37211290-796BE916-F2E9-4583-B862-B410ABBE7F8DQ37292014-5EF7CC78-E01A-4DA6-A83D-36F775F82635Q37388414-CB6ECB91-731B-4C0B-A73B-D59667219029Q37894465-E3BC8480-9FCB-4BF6-BCDA-4A1CFDA5D74DQ38112685-3A77F05C-8270-4BF8-8880-B44E459D60FEQ38514510-A98FA348-0473-4A65-800F-1564DC1CA6C9Q39340599-76922465-57AF-4FCB-9B8E-1C2AC86C5F18Q41898454-FACD6A25-75A9-4705-8250-DE38AAC72A8CQ42028666-98B64932-2977-4E7B-B7F8-1E7AE6746159Q42209021-5432750F-8E5B-4E8B-B352-5F5B9EEA29D5Q42726079-14550A05-F6B7-4CEF-92E5-2B24A8923822Q53695393-AE6A5FBF-5259-4A39-ADE1-5726953DC0D5
P2860
Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@ast
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@en
type
label
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@ast
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@en
prefLabel
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@ast
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@en
P2093
P1433
P1476
Myelosuppressive conditioning ...... oses of syngeneic bone marrow.
@en
P2093
P304
P407
P577
1994-02-01T00:00:00Z